Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie, Zhengfei Zhu

ABSTRACT

BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions. More... »

PAGES

44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1

DOI

http://dx.doi.org/10.1186/s13014-019-1240-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112739159

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30866974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ni", 
        "givenName": "Jianjiao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Guodong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Xi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Jialei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yida", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zou", 
        "givenName": "Liqing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yuan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Wenzhou Medical University", 
          "id": "https://www.grid.ac/institutes/grid.414906.e", 
          "name": [
            "Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Congying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shanghai Medical College of Fudan University", 
          "id": "https://www.grid.ac/institutes/grid.11841.3d", 
          "name": [
            "Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Zhengfei", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.2016.9839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003526472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-12-0868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007331796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2014.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008009645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.0539", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016158843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcdb.2016.09.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016585125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016737978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2013.11.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019077778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2014.1003644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027632484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029331288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1006448", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029333869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035605294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.prro.2016.05.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038999889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.3312", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040085264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860802662722", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040375196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.0138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042043060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2014.12.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043860460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1214886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046181766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182745948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047119041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep07268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047997157", 
          "https://doi.org/10.1038/srep07268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmct0806951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050338991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)30123-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074187710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079320625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.71.5904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085191926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30339-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085964284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2017.395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092730269", 
          "https://doi.org/10.1038/bjc.2017.395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103369506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fonc.2018.00154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103883556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7150/jca.24950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103988345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.5841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104022577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106916204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106933161"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown.\nMETHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2.\nRESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p\u2009=\u20090.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p\u2009=\u20090.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p\u2009=\u20090.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p\u2009=\u20090.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p\u2009=\u20090.048).\nCONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13014-019-1240-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036451", 
        "issn": [
          "1748-717X"
        ], 
        "name": "Radiation Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses", 
    "pagination": "44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30866974"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101265111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13014-019-1240-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112739159"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13014-019-1240-1", 
      "https://app.dimensions.ai/details/publication/pub.1112739159"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78970_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13014-019-1240-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13014-019-1240-1'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      62 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13014-019-1240-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc01bede79336444cabe09bc3d9085baa
4 schema:citation sg:pub.10.1038/bjc.2017.395
5 sg:pub.10.1038/srep07268
6 https://doi.org/10.1001/jama.2016.9839
7 https://doi.org/10.1016/j.ijrobp.2013.11.010
8 https://doi.org/10.1016/j.ijrobp.2014.12.010
9 https://doi.org/10.1016/j.jtho.2017.12.006
10 https://doi.org/10.1016/j.prro.2016.05.004
11 https://doi.org/10.1016/j.radonc.2014.12.009
12 https://doi.org/10.1016/j.semcdb.2016.09.016
13 https://doi.org/10.1016/s0140-6736(17)30123-x
14 https://doi.org/10.1016/s1470-2045(17)30339-x
15 https://doi.org/10.1056/nejmct0806951
16 https://doi.org/10.1056/nejmoa1006448
17 https://doi.org/10.1056/nejmoa1214886
18 https://doi.org/10.1056/nejmoa1408440
19 https://doi.org/10.1080/02841860802662722
20 https://doi.org/10.1093/annonc/mds124
21 https://doi.org/10.1093/annonc/mdt572
22 https://doi.org/10.1093/annonc/mdw305
23 https://doi.org/10.1093/annonc/mdy121
24 https://doi.org/10.1093/annonc/mdy405
25 https://doi.org/10.1097/jto.0000000000000648
26 https://doi.org/10.1097/jto.0b013e3182745948
27 https://doi.org/10.1158/1535-7163.mct-12-0868
28 https://doi.org/10.1200/jco.2007.15.3312
29 https://doi.org/10.1200/jco.2014.59.0539
30 https://doi.org/10.1200/jco.2015.62.0138
31 https://doi.org/10.1200/jco.2016.71.5904
32 https://doi.org/10.1200/jco.2017.77.5841
33 https://doi.org/10.3111/13696998.2014.1003644
34 https://doi.org/10.3322/caac.21492
35 https://doi.org/10.3389/fonc.2018.00154
36 https://doi.org/10.7150/jca.24950
37 schema:datePublished 2019-12
38 schema:datePublishedReg 2019-12-01
39 schema:description BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown. METHODS: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Disease progression in original sites (primary/metastatic), new sites, or both, are classified as original failure (OF), distant failure (DF) and ODF, respectively. Progression free survival, from crizotinib initiation to the first disease progression, and from that to the second disease progression, were calculated as PFS1 and PFS2. RESULTS: Ninety-three patients were identified. With a median follow up of 22.0 (range, 2.0-72.0) months, 52 patients had crizotinib-treatment failure. The frequencies of OF, ODF, and DF, were 50.0, 26.9, and 23.1%, respectively. Histology, primary tumor size and presence of BBM, were independently associated with OF, using competing risks analyses. The brain was the most common site of initial disease progression. Patients with BBM had a significant higher possibility developing multiple-progressive lesions in the brain (p = 0.002). Importantly, four of the ten patients who had baseline oligo-metastatic cranial disease but didn't receive upfront brain radiation, developed multiple-progressive disease in the brain. Brain radiation before crizotinib could alter the disease failure patterns and improve PFS1 among patients with BBM (p = 0.006). Extracranial radiation was efficient in controlling symptoms but it was not associated with PFS1 (p = 0.223), and the majority of patients were eligible for salvage radiotherapy upon disease progression to crizotinib. By the time of data cut-off, 28 patients had second disease progression, with a median PFS2 of 7.0 (95% CI 5.4-8.6) months and salvage radiotherapy significantly prolonged PFS2 (p = 0.003). Additionally, patients receiving any radiotherapy during their treatment course had a significant longer overall survival (p = 0.048). CONCLUSIONS: Among patients with baseline oligo-metastatic brain lesions which are suitable for stereotactic radiosurgery, upfront brain radiotherapy provides considerable clinical benefits. While, extracranial radiation may be deferred in asymptomatic patients with multiple-metastatic lesions.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf Nc9bc2f1a539d44aab101f340e6830219
44 Nfb23e4edd9264ffe9765814b0c010ba0
45 sg:journal.1036451
46 schema:name Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses
47 schema:pagination 44
48 schema:productId N1d0904f753f84388b1e3fa175ddb6113
49 N2f404099a17d456d882fe87dfc95cfbe
50 N92552ee998904fa1b7c8b629aa92e744
51 N927be6f240c64c9fbe0f61883d444355
52 Nc77e30f4a995408292994114b1fa2175
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112739159
54 https://doi.org/10.1186/s13014-019-1240-1
55 schema:sdDatePublished 2019-04-11T13:20
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N04c611b781544354983c6afbd439e426
58 schema:url https://link.springer.com/10.1186%2Fs13014-019-1240-1
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N04c611b781544354983c6afbd439e426 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N04f65b407d444312bdb4b96a95065cea rdf:first Nf27eaf4e3ac44c6b8bdf789166fc29b1
65 rdf:rest N4b8dccc861b64cefb3081e9342e29596
66 N181d0f52efde480bb375d8a3c668222c rdf:first N6f8fb0cd27414451a333d673549665c2
67 rdf:rest Nf37dba62ab684131b57418984856ba2a
68 N1d0904f753f84388b1e3fa175ddb6113 schema:name readcube_id
69 schema:value b71775b5bfb19f6595306d6380c59c9381c201c46e861e0ef9b464d000d670b7
70 rdf:type schema:PropertyValue
71 N2c649b7864da4666838ed0043d6505e1 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
72 schema:familyName Zou
73 schema:givenName Liqing
74 rdf:type schema:Person
75 N2c916228539b4efbb952834ccd08cccc schema:affiliation https://www.grid.ac/institutes/grid.414906.e
76 schema:familyName Xie
77 schema:givenName Congying
78 rdf:type schema:Person
79 N2d284678f4de467b948bd47147126a2b rdf:first N2c649b7864da4666838ed0043d6505e1
80 rdf:rest N181d0f52efde480bb375d8a3c668222c
81 N2f404099a17d456d882fe87dfc95cfbe schema:name doi
82 schema:value 10.1186/s13014-019-1240-1
83 rdf:type schema:PropertyValue
84 N3b8510b5d0b041cd835eaf57f70526c6 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
85 schema:familyName Ni
86 schema:givenName Jianjiao
87 rdf:type schema:Person
88 N4b8dccc861b64cefb3081e9342e29596 rdf:first Nf1f508b6131f4bab9de1bbfab5d67e99
89 rdf:rest Naf9a6e94ca0949c48b214767f0005447
90 N6f8fb0cd27414451a333d673549665c2 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
91 schema:familyName Li
92 schema:givenName Yuan
93 rdf:type schema:Person
94 N8a43a6d004354bdfa0d419d0b9e54caa schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
95 schema:familyName Li
96 schema:givenName Yida
97 rdf:type schema:Person
98 N92552ee998904fa1b7c8b629aa92e744 schema:name nlm_unique_id
99 schema:value 101265111
100 rdf:type schema:PropertyValue
101 N927be6f240c64c9fbe0f61883d444355 schema:name pubmed_id
102 schema:value 30866974
103 rdf:type schema:PropertyValue
104 N9d0e88da9bc044e985d07857b463ee2c rdf:first Ne5942932e877407c991a6812cec70312
105 rdf:rest N04f65b407d444312bdb4b96a95065cea
106 N9f23add1aae845a19ceebc502db39084 rdf:first Nefff4153dd6d4efcbc0c973944b980c5
107 rdf:rest N9d0e88da9bc044e985d07857b463ee2c
108 Naf9a6e94ca0949c48b214767f0005447 rdf:first N8a43a6d004354bdfa0d419d0b9e54caa
109 rdf:rest N2d284678f4de467b948bd47147126a2b
110 Nb84475c2ec804047b801b27b78ad695d rdf:first Nfa7d492706ad4fb19d6973d5e21f2f8c
111 rdf:rest rdf:nil
112 Nc01bede79336444cabe09bc3d9085baa rdf:first N3b8510b5d0b041cd835eaf57f70526c6
113 rdf:rest N9f23add1aae845a19ceebc502db39084
114 Nc77e30f4a995408292994114b1fa2175 schema:name dimensions_id
115 schema:value pub.1112739159
116 rdf:type schema:PropertyValue
117 Nc9bc2f1a539d44aab101f340e6830219 schema:volumeNumber 14
118 rdf:type schema:PublicationVolume
119 Ne5942932e877407c991a6812cec70312 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
120 schema:familyName Yang
121 schema:givenName Xi
122 rdf:type schema:Person
123 Nefff4153dd6d4efcbc0c973944b980c5 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
124 schema:familyName Li
125 schema:givenName Guodong
126 rdf:type schema:Person
127 Nf1f508b6131f4bab9de1bbfab5d67e99 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
128 schema:familyName Wang
129 schema:givenName Jialei
130 rdf:type schema:Person
131 Nf27eaf4e3ac44c6b8bdf789166fc29b1 schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
132 schema:familyName Chu
133 schema:givenName Li
134 rdf:type schema:Person
135 Nf37dba62ab684131b57418984856ba2a rdf:first N2c916228539b4efbb952834ccd08cccc
136 rdf:rest Nb84475c2ec804047b801b27b78ad695d
137 Nfa7d492706ad4fb19d6973d5e21f2f8c schema:affiliation https://www.grid.ac/institutes/grid.11841.3d
138 schema:familyName Zhu
139 schema:givenName Zhengfei
140 rdf:type schema:Person
141 Nfb23e4edd9264ffe9765814b0c010ba0 schema:issueNumber 1
142 rdf:type schema:PublicationIssue
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:journal.1036451 schema:issn 1748-717X
150 schema:name Radiation Oncology
151 rdf:type schema:Periodical
152 sg:pub.10.1038/bjc.2017.395 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092730269
153 https://doi.org/10.1038/bjc.2017.395
154 rdf:type schema:CreativeWork
155 sg:pub.10.1038/srep07268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047997157
156 https://doi.org/10.1038/srep07268
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1001/jama.2016.9839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003526472
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.ijrobp.2013.11.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019077778
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.ijrobp.2014.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008009645
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.jtho.2017.12.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099711099
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.prro.2016.05.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038999889
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.radonc.2014.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043860460
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.semcdb.2016.09.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016585125
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0140-6736(17)30123-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1074187710
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s1470-2045(17)30339-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1085964284
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1056/nejmct0806951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050338991
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1056/nejmoa1006448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029333869
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1056/nejmoa1214886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046181766
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1080/02841860802662722 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040375196
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1093/annonc/mds124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035605294
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1093/annonc/mdt572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016737978
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/annonc/mdw305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079320625
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/annonc/mdy121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103369506
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/annonc/mdy405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106933161
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1097/jto.0000000000000648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029331288
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1097/jto.0b013e3182745948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047119041
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1158/1535-7163.mct-12-0868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007331796
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2007.15.3312 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040085264
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2014.59.0539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016158843
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1200/jco.2015.62.0138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042043060
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2016.71.5904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085191926
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.2017.77.5841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104022577
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3111/13696998.2014.1003644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027632484
213 rdf:type schema:CreativeWork
214 https://doi.org/10.3322/caac.21492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106916204
215 rdf:type schema:CreativeWork
216 https://doi.org/10.3389/fonc.2018.00154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103883556
217 rdf:type schema:CreativeWork
218 https://doi.org/10.7150/jca.24950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103988345
219 rdf:type schema:CreativeWork
220 https://www.grid.ac/institutes/grid.11841.3d schema:alternateName Shanghai Medical College of Fudan University
221 schema:name Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
222 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
223 Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China
224 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
225 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, 200032, Shanghai, China
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.414906.e schema:alternateName First Affiliated Hospital of Wenzhou Medical University
228 schema:name Radiotherapy and Chemotherapy Department, the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...